Osteoporosis in severe congenital neutropenia treated with granulocyte colony‐stimulating factor
- 1 April 1995
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 89 (4), 927-928
- https://doi.org/10.1111/j.1365-2141.1995.tb08441.x
Abstract
Recombinant human granulocyte colony‐stimulating factor (G‐CSF) has substantially improved life expectancy for children with severe congenital neutropenia (SCN). Severe osteoporosis, reported in this population, may relate to the disease process, or be a therapeutic side‐effect. This report details bone loss, quantitated absorptiometrically and histomorphometrically, in a child with SCN and vertebral collapse, and the positive response to anabolic steroid and bisphosphonate therapy.Keywords
This publication has 6 references indexed in Scilit:
- Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropeniasBritish Journal of Haematology, 1994
- A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropeniaBlood, 1993
- Reference values for radial bone width and mineral content using single photon absorptiometry in healthy children aged 4 to 10 yearsActa Paediatrica, 1992
- In vitro functions of neutrophils induced by treatment with rhG‐CSF in severe congenital neutropeniaEuropean Journal of Haematology, 1991
- Bone growth and mineralisation in children aged 4 to 10 yearsBone and Mineral, 1991
- Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropeniaBlood, 1990